Abstract
Summary
There are no simple answers to questions such as ‘Which antidepressant is most likely to cause seizures?’ or ‘Which antipsychotic drug is the safest to use in a patient with a seizure disorder?’
The risk of psychotropic drug-induced seizures is dependent on many factors beyond inherent differences in the propensity of individual drugs to lower seizure threshold. Individual patient variables that affect the likelihood of drug-induced seizures occurring include a history of epilepsy or seizures, a family history of epilepsy, and postnatal brain damage, head trauma and dementia. Once a drug is selected, seizure risk is directly dependent on dosage, rate and amount of dose titration, and concurrent use of other drugs.
Setting aside these other risk factors, the likelihood of drug-induced seizures occurring does differ among psychotropic drugs. Among antipsychotic drugs, clozapine is associated with the highest risk of seizures, followed by chlorpromazine, with other phenothiazines and risperidone having a lower risk and haloperidol the least risk.
Among antidepressants, maprotiline, amoxapine, amfebutamone (bupropion) and clomipramine pose the greatest risk along with other tricyclic antidepressants in high doses. Monoamine oxidase inhibitors (MAOIs), trazodone, nefazodone and the selective serotonin (5-hydroxytryptamine; 5-HT) reuptake inhibitors (SSRIs) are associated with a lower risk of seizures.
Benzodiazepines with long elimination half-lives are less likely to cause seizures during withdrawal than those agents with short to intermediate half-lives, although the rate and amount of dosage reduction are more important variables.
Finally, most psychotropic drugs are metabolised by cytochrome P450 isoenzymes. Concurrent use of enzyme inhibitors or discontinuation of enzyme inducers may cause a significant increase in plasma concentrations of the psychotropic drug, increasing the likelihood of adverse effects and the potential for seizures.
Similar content being viewed by others
References
Rosenstein DL, Nelson JC, Jacons Sc. Seizures associated with antidepressants: a review. J Clin Psychiatry 1993; 54: 289–99
Skowron OM, Stimmel GL. Antidepressants and the risk of seizures. Pharmacotherapy 1992; 12: 18–22
Davidson J. Seizures and bupropion: a review. J Clin Psychiatry 1989; 50: 256–61
Schaul N, DeGreef G, Ney GC. Psychotropic drugs and seizures. In: Kane JM, Lieberman JA, editors. Adverse effects of psychotropic drugs. New York: Guilford Press, 1992: 321–37
Cold JA, Wells BG, Froemming JH. Seizure activity associated with antipsychotic therapy. DICP 1990; 24: 601–6
Small JG, Milstein V, Small IF, et al. Computerized EEG profiles of haloperidol, chlorpromazine, c1ozapine, and placebo in treatment resistant schizophrenia. Clin Electroencephalogr 1987; 18: 124–35
Trimble M. The relationship between epilepsy and schizophrenia: a biochemical hypothesis. Biol Psychiatry 1977; 12: 299–304
Olson KR, Kearney TE, Dyer JE, et al. Seizures associated with poisoning and drug overdose. Am J Emerg Med 1993; 11: 565–8
Spontaneous epileptic seizures and electroencephalographic changes in the course of phenothiazine therapy. Neurology 1967; 17: 869–77
Hil TM, Soldatos C. Epileptogenic side effects of psychotropic drugs. JAMA 1980; 244: 1460–3
Kurtzke JE. Seizures with promazine, preliminary report. J Nerv Ment Dis 1957; 125: 119–25
Prien RF, Cole JO. High dose chlorpromazine therapy in chronic schizophrenia. Arch Gen Psychiatry 1968; 18: 482–95
Quitkin F, Rifkin A, Klein DE. Very high dosage versus standard dosage fluphenazine in schizophrenia. Arch Gen Psychiatry 1975; 32: 1276–81
Remick RA, Fine SH. Antipsychotic drugs and seizures. J Clin Psychiatry 1979; 40: 78–80
Devinsky O, Honigfeld G, Patin J. Clozapine-related seizures. Neurology 1991; 41: 369–71
Pacia SV, Devinsky O. Clozapine-related seizures. Neurology 1994; 44: 2247–9
Welch J, Manschreck T, Redmond D. Clozapine-induced seizures and EEG changes. J Neuropsychiatry Clin Neurosci 1994; 6: 250–6
Gunther W, Baghai T, Naber O, et al. EEG alterations and seizures during treatment with c1ozapine. Pharmacopsychiatry 1993; 26: 69–74
Tiihonen J, Nousiainen U, Hakola P, et al. EEG abnormalities associated with c10zapine treatment [letter). Am J Psychiatry 1991; 148: 1406
Liukkonen J, Koponen HJ, Nousiainen U. Clinical picture and longterm course of epileptic seizures that occur during c1ozapine treatment. Psychiatry Res 1992; 44: 107–12
McCarthy RH. Seizures following smoking cessation in a c10zapine responder. Pharmacopsychiatry 1994; 27: 210–1
Funderburg LG, Vertrees JE, True JE, et al. Seizure following addition of erythromycin to c10zapine treatment [letter]. Am J Psychiatry 1994; 151: 1840–1
Centorrino F, Baldessarini RJ, Kando J, et al. Serum concentrations of c10zapine and its major metabolites: effects of cotreatrnent with fluoxetine or valproate. Am J Psychiatry 1994; 151: 123–5
Wilson WH, Claussen AM. Seizures associated with c10zapine treatment in a state hospital. J Clin Psychiatry 1994; 55: 184–8
Devinsky O, Pacia SV. Seizures during c10zapine therapy. J Clin Psychiatry 1994; 55 (9) Suppl.B: 153–6
Kando JC, Tohen M, Castillo J, et al. Concurrent use of c1ozapine and valproate in affective and psychotic disorders. J Clin Psychiatry 1994; 55: 255–7
Wilson WH. Do anticonvulsants hinder clozapine treatment? Biol Psychiatry 1995; 37: 132–3
Finley P, Warner D. Potential impact of valproic acid therapy on clozapine disposition. Biol Psychiatry 1994; 36: 487–8
Cohen LJ. Risperidone. Pharmacotherapy 1994; 14: 253–65
Janssen Pharmaceutica. Risperdal package insert. Aug, 1994
Jabbari B, Bryan GE, March EE, et al. Incidence of seizures with tricyclic and tetracyclic antidepressants. Arch Neurol 1985; 42: 480–1
Peck AW, Stem WC, Watkinson C. Incidence of seizures during treatment with tricyclic antidepressant drugs and bupropion. J Clin Psychiatry 1983; 44 (5Pt2): 197–201
Jick H, Dinan BJ, Hunter JR, et al. Tricyclic antidepressants and convulsions. J Clin Psychopharmacol 1983; 3: 182–5
Preskorn SH, Fast GA. Tricyclic antidepressant-induced seizures and plasma drug concentration. J Clin Psychiatry 1992; 53: 160–2
Forstl H, Pohlmann-Eden B. Monitoring antidepressant-induced cerebral hyperexcitability [letter]. J Clin Psychiatry 1993; 54: 201
Ojemann LM, Friel PN, Trejo WJ, et al. Effect of doxepin on seizure frequency in depressed epileptic patients. Neurology 1983; 33: 646–8
Wroblewski BA, McColgan K, Smith K, et al. The incidence of seizures during tricyclic antidepressant drug treatment in a brain-injured population. J Clin Psychopharmacol 1990; 10: 124–8
Hulten BA, Heath A. Clinical aspects of tricyclic antidepressant poisoning. Acta Med Scand 1983; 213: 275–8
Lavoie FW, Gansert GG, Weiss RE. Value of initial ECG findings and plasma drug levels in cyclic antidepressant overdose. Ann Emerg Med 1990; 19: 696–700
DeVeaugh-Geis J, Landau P, Katz R. Preliminary results from a multicenter trial of clomipramine in obsessive-compulsive disorder. Psychopharmacol Bull 1989; 25: 36–40
Jermain DM, Crismon ML. Pharmacotherapy of obsessivecompulsive disorder. Pharmacotherapy 1990; 10: 175–98
Pascual J, Combarros O, Berciano J. Partial status epileptic us following single low dose of chlorimipramine in a patient on MAO inhibitor treatment. Clin Neuropharmacol 1987; 10: 565–7
Jick SS, Jick H, Knauss TA, et al. Antidepressants and convulsions. J Clin Psychopharmacol 1992; 12: 241–5
Buckley NA, Dawson AH, Whyte JM, et al. Greater toxicity in overdose of dothiepin than of other tricyclic antidepressants. Lancet 1994; 343: 159–62
Dessain EC, Schatzberg AF, Woods BT, et al. Maprotiline treatment in depression. Arch Gen Psychiatry 1986; 43: 86–90
Knudsen K, Heath A. Effects of self poisoning with maprotiline. BMJ 1984; 288: 601–3
Wyss PA, Serena S, Meier PJ. Dose-dependency of seizures in maprotiline (Ludiomil) intoxications [abstract]. Vet Hum Toxicol 1993; 35: 341
Smith RS, Ayd FJ. A critical appraisal of amoxapine. J Clin Psychiatry 1981; 42: 238–42
Litovitz TL, Troutman WG. Amoxapine overdose. JAMA 1983; 250: 1069–71
Home RL, Ferguson JM, Pope HG, et al. Treatment of bulimia with bupropion: a multicenter controlled trial. J Clin Psychiatry 1988; 49: 262–6
Johnston JA, Lineberry CG, Ascher JA, et al. A 102-center prospective study of seizure in association with bupropion. J Clin Psychiatry 1991; 52: 450–6
Weber JJ. Seizure activity associated with fluoxetine therapy. Clin Pharm 1989; 8: 296–8
Messiha FS. Fluoxetine: adverse effects and drug-drug interactions. Clin Toxicol 1993; 31: 603–30
Grady TA, Pigott TA, L’Heureux F, et al. Seizure associated with fluoxetine and adjuvant buspirone therapy [letter]. J Clin Psychopharmacol 1992; 12: 70–1
Levine R, Kenin M, Hoffman JS, et al. Grand mal seizures associated with use of fluoxetine [letter]. J Clin Psychopharmacol 1994; 14: 145–6
Braitberg G, Curry Sc. Seizure after isolated fluoxetine overdose. Ann Emerg Med 1992; 26: 234–7
Myers LB, Dean BS, Krenzolok EP. Sertraline (Zoloft): overdose assessment of a new antidepressant [abstract]. Vet Hum Toxicol 1993; 35: 341
Boyer WF, Blumhardt CL. The safety profile of paroxetine. J Clin Psychiatry 1992; 53 Suppl.2: 61–6
Wagner W, Plekkenpol B, Gray TE, et al. Review of fluvoxamine safety database. Drugs 1992; 43 Suppl.2: 48–54
Palmer KJ, Benfield P. Fluvoxamine: an overview of its pharmacological properties and a review of its use in non-depressive disorders. CNS Drugs 1994; 1: 57–87
Spina E, Campo GM, Avenoso A, et al. Interaction between fluvoxamine and imipramine/desipramine in four patients. Ther Drug Monit 1992; 14: 194–6
Preskorn SH. Recent pharmacologic advances in antidepressant therapy for the elderly. Am J Med 1993; 94 Suppl. 5A: 2S–12S
Sternbach H. Fluoxetine-clomipramine interaction [letter]. J Clin Psychiatry 1995; 56: 171–2
Tasini M. Complex partial seizures in a patient receiving trazodone. J Clin Psychiatry 1986; 47: 318–9
Balestrieri G, Cerudelli B, Ciaccio S, et al. Hyponatremia and seizure due to overdose of trazodone [letter]. BMJ 1992; 304: 686
Gamble DE, Peterson LG. Trazodone overdose: four years of experience from voluntary reports. J Clin Psychiatry 1986; 47: 544–6
Bristol-Myers Squibb Company. Serzone package insert. Jan, 1995
Henry JA, Martin AJ. The risk-benefit assessment of antidepressant drugs. Med Toxicol 1987; 2: 445–62
Rabkin J, Quitkin F, Harrison W, et al. Adverse reactions to monoamine oxidase inhibitors. Part I: a comparative study. J Clin Psychopharmacol 1984; 4: 270–8
Lieberman JA, Kane JM, Reife R. Neuromuscular effects of monoamine oxidase inhibitors. J Clin Psychopharmacol 1985; 5: 221–8
Sternbach H. The serotonin syndrome. Am J Psychiatry 1991; 148: 705–13
Moll E, Hetzel W. Moclobemide (Ro 11-1163) safety in depressed patients. Acta Psychiatr Scand 1990; 90 Suppl.360: 69–70
Freeman H. Moclobemide. Lancet 1993; 342: 1528–32
Zaccara G, Muscas GC, Messori A. Clinical features, pathogenesis and management of drug-induced seizures. Drug Saf 1990; 5: 109–51
Spiller HA, Krenzelok EP, Cookson E. Carbamazepine overdose: a prospective study of serum levels and toxicity. Clin Toxicol 1990; 28 (4): 445–58
Small JG, Milstein V. Lithium interactions: lithium and electroconvulsive therapy. J Clin Psychopharmacol 1990; 10 (5): 346–50
Seymour JF. Carbamazepine overdose: features of 33 cases. Drug Saf 1993; 8 (1): 81–8
Malow BA, Blaxton TA, Stertz B, et al. Carbamazepine withdrawal: effects of taper rate on seizure frequency. Neurology 1993; 43: 2280–4
Stoll AL, Banov M, Kolbrener M, et al. Neurologic factors predict a favorable response in bipolar and schizoaffective disorders. J Clin Psychopharmacol 1994; 14(5): 311–3
Hollister LE. Pharmacology and pharmacokinetics of minor tranquilizers. Psychiatr Ann 1981; 11Suppl.: 26–31
Perry PJ. Assessment of addiction liability of benzodiazepines and buspirone. Drug Intell Clin Pharrn 1985; 19: 657–9
Warner MD, Peabody CA, Bouros NN. Alprazolam and withdrawal seizures. J Nerv Ment Dis 1990; 178 (3): 208–9
Hollister LE, Muller-Oerlinghausen B, Rickels K, et al. Clinical uses ofbenzodiazepines. J Clin Psychopharmacol 1993; 13 (6 Suppl.1): 1S–161S
Sugai K. Seizures with clonazepam: discontinuation and suggestions for safe discontinuation rates in children. Epilepsia 1993; 34 (6): 1089–97
Spivey WH. Flumazenil and seizures: analysis of 43 cases. Clin Ther 1992; 14 (2): 292–305
Haverkos GP, DiSalvo RP, Imhoff TE. Fatal seizures after flumazenil administration in a patient with mixed overdose. Ann Pharmacother 1994; 28: 1347–9
Greenberg DB. Buspirone for myoclonus, obsessive fears, and confusion. Psychosomatics 1993; 34 (3): 270–2
Lowenstein DH, Massa SM, Rowbotham MC, et al. Acute neurologic and psychiatric complications associated with cocaine abuse. Am J Med 1987; 83: 841–6
Washton AM, Tatarsky A. Adverse effects of cocaine abuse. In: Problems of drug dependence: NIDA Research Monograph Series 49. Washington (DC): US Department of Health and Human Services, 1983: 247–54
Alldredge BK, Lowenstein DH, Simon RP. Seizures associated with recreational drug abuse. Neurology 1989; 39: 1037–9
Sands BF, Ciraulo DA. Cocaine drug-drug interactions. J Clin Psychopharmacol 1992; 12 (6): 445–7
Holland RW, Marx JA, Earnest MP, et al. Grand mal seizures temporally related to cocaine use: clinical and diagnostic features. Ann Emerg Med 1992; 21: 772–6
Dhuna A, Pascual-Leone A. New onset seizures after first-time cocaine abuse. Epilepsia 1990; 31 (5): 605–6
Skolnick A. Cocaine use in pregnancy: physicians urged to look for problem where they least expect it. JAMA 1990; 264 (3): 306–8
Wroblewski BA, Leary JM, Phelan AM, et al. Methylphenidate and seizure frequency in brain injured patients with seizure disorders. J Clin Psychiatry 1992; 53: 86–9
Meisel SB, Welford PK. Seizures associated with high-dose intravenous morphine containing sodium bisulfite preservative. Ann Pharmacother 1992; 26: 1515–7
Parkinson SK, Bailey SL. Myoclonic seizure activity with chronic high-dose spinal opioid administration. Anesthesiology 1990; 72: 743–5
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Stimmel, G.L., Dopheide, J.A. Psychotropic Drug-Induced Reductions in Seizure Threshold. CNS Drugs 5, 37–50 (1996). https://doi.org/10.2165/00023210-199605010-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00023210-199605010-00004